Depot Buprenorphine a Shot in the Arm for Opioid Addiction? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
May 12, 2021
Patients report greater satisfaction with weekly, monthly buprenorphine
People with opioid dependence reported being more satisfied and more compliant with weekly or monthly depot buprenorphine versus sublingual buprenorphine, researchers reported.
In an open-label, 24-week randomized trial done at six outpatient clinical sites in Australia, the self-reported global satisfaction score was significantly higher for the depot group compared with the sublingual group at a mean TSQM (Treatment Satisfaction Questionnaire for Medication v1.4) score of 82.5 versus 74.3, for a difference of 8.2 (95% CI 1.7-14.6,
P=0.01), according to Fredrik Tiberg, PhD, of Camurus in Lund, Sweden, and co-authors (TQSM ranges from 0-100 with higher score indicating greater satisfaction).
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
- Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine
- The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment
- Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life
News provided by
Share this article
LUND, Sweden, May 10, 2021 /PRNewswire/ Camurus (NASDAQ STO: CAMX) announces today the publication in
JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly buprenorphine depot injections (Buvidal
PRESS RELEASE Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life Lund, Sweden - 10 May 2021 - Camurus (NASDAQ STO: CAMX) announces today the publication in JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly buprenorphine depot injections (Buvidal®) versus daily sublingual buprenorphine.